PharmaMar Signs Lurbinectedin Licensing and Commercialization Agreement with Lotus Pharmaceutical in Taiwan

PharmaMar Signs Lurbinectedin Licensing and Commercialization Agreement with Lotus Pharmaceutical in Taiwan

By, Admin 13 November 2021

PharmaMar S.A. (MSE: PHM) today announced that it has entered into a licensing agreement with Lotus Pharmaceutical CO. LTD. ("Lotus", TWSE: 1795) to market the anticancer drug urbinectedin in Taiwan. Under the terms of the license and commercialization agreement, PharmaMar will receive an undisclosed upfront payment and will be eligible for additional compensation, including regulatory payments and milestone sales payments. PharmaMar will retain the manufacturing rights and sell the product to Lotus for clinical and commercial use. Lotus will seek marketing approval in Taiwan and will have the right to offer the product for sale exclusively after receipt. Lurbinectedin received fast-track approval from the United States Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer in 2020. Additionally, in 2021, lurbinectedin received marketing approval in the United States. United Arab Emirates, Canada, Australia and Singapore. Luis Mora, Managing Director of PharmaMar's Oncology and Virology Business Units, said:

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!